Every case of Ductal Carcinoma in situ (stage 0 breast cancer) is treated in the US whether it is aggressive or indolent. Our objective was to identify biomarkers of indolence vs aggressiveness in DCI
BackgroundHepatocellular carcinoma (HCC) is a highly prevalent and fatal cancer. The role of PANoptosis, a novel form of programmed cell death, in HCC is yet to be fully understood. This study focuses
HCC is one of the most common types of malignancies worldwide and the fourth-leading cause of cancer deaths. Thus, there is an urgent need to search for novel targeted therapies in HCC. 186 m6a-relate
